Q-VANT Biosciences

🎉 Wishing you a Happy End of the Year from Q-VANT Biosciences! As we step into 2025, we are filled with gratitude for the partnerships, developments, and progress we shared with you in the past year in advancing vaccine adjuvant technology and supply security. This year, our team has worked to contribute to the global effort in developing and scaling up the processes to create and deliver safer, effective and more sustainable saponin adjuvants and therapies: ·        In collaboration with Tulane University, financed by NIH, we started to develop an Oral adjuvant platform https://lnkd.in/gtD6y6Vz ·        The construction finished for our state-of-the-art Quillaja-based adjuvant factory. ·        Our team grew. ·        Supporting SPI Pharma at The World Vaccine Congress, CBIOPC, CPHI. ·        We received interest from 31 vaccine developers and manufacturers in our saponin adjuvants. Wishing our colleagues and partners a healthy and impactful year ahead. More breakthroughs will be coming next year from Q-VANT Biosciences, through collaboration, and generating positive impact in the field of infectious diseases and therapy. Cheers to a Happy New Year! 🥂 #VaccineAdjuvant #NewYear2025

Embracing the spirit of Christmas Spirit at Q-VANT! 🌟 The Q-VANT Biosciences team wishes all patients suffering from a disease and their families the very best in this festive season. We hope you have a healthy, loving, and memorable Christmas! In the spirit of giving, we're grateful for the opportunity to contribute to the well-being of patients worldwide through enabling sustainable, and open-access vaccine adjuvants. I'm wishing everyone a happy, healthy, and hopeful Christmas! #Patients #Christmas #OpenAccessToHealth

Welcome to the Q-VANT team, Kevin! ⚙️✅ We’re thrilled to post that kevin sepulveda joined us as a Specialist in Process and Equipment Qualification. His 7 years of experience in the pharmaceutical industry and his expertise are instrumental in ensuring regulatory compliance, optimizing production efficiency, and advancing quality assurance as we deliver high-quality adjuvants for next-generation vaccines. With Kevin on board, we’re further strengthening our commitment to excellence in manufacturing and innovation in vaccine development. Let’s give Kevin a warm welcome as he embarks on this exciting journey with Q-VANT! #Welcome #QVANTBiosciences #VaccineAdjuvant

Corporate update from Q-VANT Biosciences! We’re thrilled to welcome Cristian Rosselot as Chief Financial Officer! Cristian brings a wealth of experience in financial leadership, strategic planning, and driving growth in innovative industries. As Q-VANT Biosciences continues the path of saponin adjuvant development and manufacturing, Cristian’s expertise will be instrumental in advancing our mission to ensure business continuity and agility. Welcome Cristian to the Q-VANT Biosciences team! #QVANT #CFO #Adjuvant #Biotech

Q-VANT Biosciences new state-of-the-art manufacturing facility is officially ready to start production! This cutting-edge site leverages our proprietary Q-SAP technology, enabling us to purify millions of kilograms of sustainably sourced biomass for the production of QS-21 and other saponin adjuvants for vaccine manufacturers worldwide. 🌍 With over 4,000 m² of production space and 800 m² of laboratories and offices, this facility is built for industrial-scale manufacturing. The next generation of saponins for vaccines and immunotherapies is now powered by a sustainable, secure, and high-volume production. Our platform produces saponin adjuvants without cutting down a single tree, emancipating vaccines from the limited bark supply. 🌳Q-SAP technology is 1,000-fold more efficient than traditional methods. This breakthrough ensures the reliable supply of these critical vaccine adjuvants, setting a new standard for sustainable manufacturing in the biomolecule industry. Q-VANT Biosciences is not just keeping up with the demand—we’re scaling for the future of global health. 💉 #QS21 #VaccineDevelopment #Adjuvants #GMP #Saponins #InnovationAtScale

🦠 World awareness week for Antimicrobial Resistance. Bacterial Resistance is responsible for at least 1.27 million deaths per year due mainly to the indiscriminate use of antimicrobials, generating strains of multi-resistant bacteria. To contest this growing threat, we must adopt preventive solutions to training the immune system, such as using vaccines. Vaccines adjuvanted with saponins offer a promising resource in this battle against multi-resistant bacteria. Studies have shown high immunogenicity of vaccines adjuvanted with saponins against Mycobacterium tuberculosis, Streptococcus A and B, Staphylococcus aureus, and Pertussis, presenting multi-resistance against antibiotics. Q-VANT Biosciences supports scientists in developing effective vaccines against multi-resistant bacteria. #AntimicrobialResistance #Vaccines #PreventiveMedicine #Adjuvant 1.   WHO, 2023, Antimicrobial resistance, accessed from https://lnkd.in/f8AXVGX 2.   Leroux-Roels, 2010, Evaluation of the Safety and Immunogenicity of Two Antigen Concentrations of the Mtb72F/AS02A Candidate Tuberculosis Vaccine in Purified Protein Derivative-Negative Adults, Clin Vaccine Immunol. 17(11) 3.   Soto, J. A. et al., 2019. Cellular immune response induced by surface immunogenic protein with AbISCO-100 adjuvant vaccination decreases group B Streptococcus vaginal colonization. Molecular Immunology, Volume 111, pp. 198-204. 4.   Rivera-Hernandez, T. et al., 2020. Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies. mBio, 11(2). 5.   Scully, I. L. et al., 2021. Performance of a Four-Antigen Staphylococcus aureus Vaccine in Preclinical Models of Invasive S. aureus Disease. Microorganisms, 9(1), p. 177. 6.   CDC, 2019, AR Threat Report, accessed from https://lnkd.in/eHq9zMq4

At Q-VANT Biosciences, our Q-SAP technology, integrated with direct access to sustainable quillaja plantations, represents the most reliable, environmentally responsible, and cost-effective approach for producing QS-21 and saponin adjuvants. Our proprietary process enables the production of billions of doses of QS-21 without the need to harvest a single tree, achieving a production efficiency that surpasses traditional methods by several orders of magnitude. This innovation underscores our commitment to sustainability while meeting the growing demand for high-quality adjuvants in a cost-effective manner. #Vaccines #GlobalHealth #Sustainability #HealthEquity #Quillaja

Thank you Vishnu Sargar and SPI Pharma for bringing open-access saponin adjuvants to the Vaccine World Asia Congress. Q-VANT Biosciences will actively support vaccine manufacturers during vaccine developments.

🌍 Today, we commemorate #WorldPolioDay, highlighting the progress and collective efforts in eradicating this debilitating disease. In collaboration with Tulane University, Q-VANT Biosciences participates to the development of a promising new platform for oral vaccines that could be used to prevent a variety of infectious diseases, including poliomyelitis. An oral vaccine can be vastly superior in enhancing mucosal immunity by targeting the gastrointestinal tissue or the site of infection. Saponin adjuvants constitute a promising breakthrough to enhance the immune response of inactivated vaccines at affordable cost and worldwide availability. https://lnkd.in/gtD6y6Vz #Vaccine #SaponinAdjuvant #EndPolio

Q-VANT Biosciences will attend both the CPHI and The World Vaccine Congress Europe events. Thank you SPI Pharma for welcoming Stein Løkstad and Matthieu Privat. Join us at the SPI Pharma booth to discuss the secure supply of saponin adjuvants and understand our capabilities to support vaccine developers and manufacturers. Looking forward to connecting with you! #CPHI #WVCE #QVANTBiosciences #SPIPharma